• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

转移性肾细胞癌。

Metastatic renal cell cancer.

机构信息

Department of Radiology, Aarhus University Hospital, Denmark.

出版信息

Cancer Imaging. 2013 Sep 23;13(3):374-80. doi: 10.1102/1470-7330.2013.9035.

DOI:10.1102/1470-7330.2013.9035
PMID:24061106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3783114/
Abstract

Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at most institutions although a combination of cytokine therapy and targeted therapy still is being investigated. Morphological size-based criteria (RECIST) has failed in monitoring the effect of targeted therapy in patients with mRCC, as successful therapy often does not result in a decrease in tumour size. Modifications of size-based criteria and criteria based on computed tomography (CT) contrast enhancement has been introduced. Different imaging modalities that rely on characteristics other than size such as dynamic contrast-enhanced (DCE) ultrasonography, DCE CT, DCE magnetic resonance imaging (MRI), diffusion-weighted MRI, positron emission tomography and texture analysis seem to contribute with prognostic information, even at baseline scans, and can predict tumour response early after initiating therapy. No new standard for the imaging follow-up of targeted therapy in mRCC has been established.

摘要

在大多数医疗机构中，靶向治疗是转移性肾细胞癌（mRCC）患者的首选治疗方法，尽管细胞因子治疗联合靶向治疗仍在研究中。形态学大小为基础的标准（RECIST）在监测 mRCC 患者的靶向治疗效果方面已经失败，因为成功的治疗通常不会导致肿瘤大小减小。已经引入了基于大小的标准和基于计算机断层扫描（CT）对比增强的标准的修改。依赖于大小以外的特征的不同成像方式，如动态对比增强（DCE）超声、DCE CT、DCE 磁共振成像（MRI）、弥散加权 MRI、正电子发射断层扫描和纹理分析，即使在基线扫描时，似乎也能提供预后信息，并能在开始治疗后早期预测肿瘤反应。在 mRCC 中，针对靶向治疗的影像学随访尚未建立新的标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/5be07685346d/ci13903504.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/f02a5a7a0822/ci13903501.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/891d77389c4c/ci13903502.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/3fbe276e80d5/ci13903503.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/5be07685346d/ci13903504.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/f02a5a7a0822/ci13903501.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/891d77389c4c/ci13903502.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/3fbe276e80d5/ci13903503.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f720/3783114/5be07685346d/ci13903504.jpg

相似文献

1
Metastatic renal cell cancer.转移性肾细胞癌。
Cancer Imaging. 2013 Sep 23;13(3):374-80. doi: 10.1102/1470-7330.2013.9035.
2
Targeted therapies in renal cell cancer: recent developments in imaging.肾细胞癌的靶向治疗：影像学的最新进展。
Target Oncol. 2010 Jun;5(2):95-112. doi: 10.1007/s11523-010-0146-5. Epub 2010 Jul 14.
3
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.动态对比增强 CT、MRI 和 US 测量的血管反应参数在接受舒尼替尼治疗的转移性肾细胞癌患者中的预后和预测价值。
Eur Radiol. 2018 Jun;28(6):2281-2290. doi: 10.1007/s00330-017-5220-2. Epub 2018 Jan 30.
4
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌患者的正电子发射断层扫描/计算机断层扫描联合评估。
Clin Oncol (R Coll Radiol). 2011 Jun;23(5):339-43. doi: 10.1016/j.clon.2010.11.006. Epub 2010 Dec 4.
5
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.比较四种血管内皮生长因子靶向治疗晚期肾细胞癌患者治疗后早期影像学改变（EPTIC；RECIST1.0、肿瘤退缩、CT 肿瘤密度、Choi 标准）评估疗效的价值。
Eur Urol. 2011 May;59(5):856-62. doi: 10.1016/j.eururo.2011.01.038. Epub 2011 Feb 1.
6
Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.动态对比增强计算机断层扫描作为转移性肾细胞癌患者的潜在生物标志物：丹麦肾癌研究组研究-1的初步结果
Invest Radiol. 2014 Sep;49(9):601-7. doi: 10.1097/RLI.0000000000000058.
7
Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations.评估肾细胞癌中靶向治疗的反应：技术见解和实际考虑因素。
Eur Urol. 2014 Apr;65(4):766-77. doi: 10.1016/j.eururo.2013.11.031. Epub 2013 Nov 28.
8
Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.使用[F-18]氟代胸苷-正电子发射断层扫描-磁共振对转移性肾细胞癌中受体酪氨酸激酶抑制剂治疗进行早期反应监测
Semin Roentgenol. 2014 Jul;49(3):238-41. doi: 10.1053/j.ro.2014.09.001. Epub 2014 Sep 16.
9
Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.转移性肾细胞癌的系统治疗：扩散加权 MRI 的表观扩散系数在预测早期治疗反应中的作用。
Clin Exp Med. 2020 May;20(2):277-287. doi: 10.1007/s10238-020-00612-9. Epub 2020 Feb 5.
10
Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma.用于肾细胞癌患者监测的当代成像方式。
Curr Urol Rep. 2007 Jan;8(1):38-43. doi: 10.1007/s11934-007-0019-3.

引用本文的文献

1
Navigating advanced renal cell carcinoma in the era of artificial intelligence.在人工智能时代应对晚期肾细胞癌
Cancer Imaging. 2025 Feb 18;25(1):16. doi: 10.1186/s40644-025-00835-7.
2
Implications of MTHFD2 expression in renal cell carcinoma aggressiveness.MTHFD2 表达与肾细胞癌侵袭性的关系。
PLoS One. 2024 Feb 29;19(2):e0299353. doi: 10.1371/journal.pone.0299353. eCollection 2024.
3
The Impact of miR-122 on Cancer.miR-122 对癌症的影响。

本文引用的文献

1
Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers.计算机断层扫描灌注成像在肾细胞癌中的应用：与组织病理学血管生成和预后标志物的系统比较。
Invest Radiol. 2013 Apr;48(4):183-91. doi: 10.1097/RLI.0b013e31827c63a3.
2
Imaging beyond RECIST: CT and MRI in molecular therapies.超越 RECIST 的影像学：分子治疗中的 CT 和 MRI。
Cancer Imaging. 2012 Sep 28;12(2):347-50. doi: 10.1102/1470-7330.2012.9013.
3
Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography.
Curr Pharm Biotechnol. 2024;25(12):1489-1499. doi: 10.2174/0113892010272106231109065912.
4
Sohlh2 Inhibits the Malignant Progression of Renal Cell Carcinoma by Upregulating Klotho DNMT3a.Sohlh2通过上调Klotho和DNMT3a抑制肾细胞癌的恶性进展。
Front Oncol. 2022 Jan 19;11:769493. doi: 10.3389/fonc.2021.769493. eCollection 2021.
5
miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway.miR-133b 通过抑制 ERK 信号通路影响肾细胞癌中的细胞增殖、侵袭和化疗敏感性。
Mol Med Rep. 2020 Jul;22(1):67-76. doi: 10.3892/mmr.2020.11125. Epub 2020 May 5.
6
Treatment sequences for advanced renal cell carcinoma: A health economic assessment.晚期肾细胞癌的治疗方案：一项卫生经济评估。
PLoS One. 2019 Aug 29;14(8):e0215761. doi: 10.1371/journal.pone.0215761. eCollection 2019.
7
Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.老年转移性透明细胞肾细胞癌的治疗决策：TKI 和免疫检查点抑制剂的作用。
Drugs Aging. 2019 May;36(5):395-401. doi: 10.1007/s40266-019-00644-1.
8
MicroRNA-195: a review of its role in cancers.微小RNA-195：对其在癌症中作用的综述
Onco Targets Ther. 2018 Oct 17;11:7109-7123. doi: 10.2147/OTT.S183600. eCollection 2018.
9
miR-514a-3p functions as a tumor suppressor in renal cell carcinoma.miR-514a-3p在肾细胞癌中发挥肿瘤抑制作用。
Oncol Lett. 2017 Nov;14(5):5624-5630. doi: 10.3892/ol.2017.6855. Epub 2017 Aug 31.
10
miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis.微小RNA-125b与肾癌细胞的迁移、侵袭及凋亡相关。
Oncol Lett. 2017 Jun;13(6):4512-4520. doi: 10.3892/ol.2017.5985. Epub 2017 Apr 4.
动态对比增强 CT 评估肿瘤血管支持的现状和指南。
Eur Radiol. 2012 Jul;22(7):1430-41. doi: 10.1007/s00330-012-2379-4. Epub 2012 Feb 26.
4
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.功能磁共振成像技术显示舒尼替尼治疗的肾细胞癌患者早期血管变化：一项初步研究。
Cancer Imaging. 2012 Jan 12;11(1):259-65. doi: 10.1102/1470-7330.2011.0032.
5
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.分子靶向治疗早期随访中转移性肾细胞癌病变的大小和密度变化过程。
Urol Oncol. 2012 Sep;30(5):695-703. doi: 10.1016/j.urolonc.2010.10.011. Epub 2011 Aug 24.
6
Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.转移性肾细胞癌酪氨酸激酶抑制剂反应评估：CT 纹理作为预测生物标志物。
Radiology. 2011 Oct;261(1):165-71. doi: 10.1148/radiol.11110264. Epub 2011 Aug 3.
7
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.比较四种血管内皮生长因子靶向治疗晚期肾细胞癌患者治疗后早期影像学改变（EPTIC；RECIST1.0、肿瘤退缩、CT 肿瘤密度、Choi 标准）评估疗效的价值。
Eur Urol. 2011 May;59(5):856-62. doi: 10.1016/j.eururo.2011.01.038. Epub 2011 Feb 1.
8
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌患者的正电子发射断层扫描/计算机断层扫描联合评估。
Clin Oncol (R Coll Radiol). 2011 Jun;23(5):339-43. doi: 10.1016/j.clon.2010.11.006. Epub 2010 Dec 4.
9
EAU guidelines on renal cell carcinoma: the 2010 update.EAU 指南：肾细胞癌——2010 年更新版。
Eur Urol. 2010 Sep;58(3):398-406. doi: 10.1016/j.eururo.2010.06.032. Epub 2010 Jul 12.
10
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.转移性肾细胞癌：动态对比增强 CT 评价抗血管生成治疗。
Radiology. 2010 Aug;256(2):511-8. doi: 10.1148/radiol.10091362. Epub 2010 Jun 15.